Drug-Eluting Stents vs. CABG for Left-Main Disease
Even after accounting for the likelihood that specific patients would undergo one type of revascularization versus the other, we still need long-term randomized data to determine whether left-main stenting is ready for prime time.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)